Why the study?
Complex pathologic mechanisms of HFpEF have prevented the establishment of a standard diagnosis and treatment regimen, driving continued efforts to identify appropriate diagnostic technologies and effective therapies.
Answers are grounded in this paper and cite their sources.
This review summarizes recent advances in HFpEF, highlighting the diagnostic value of CMR and the therapeutic benefits of SGLT2 inhibitors and GLP-1 receptor agonists.
射血分数保留性心衰(Heart Failure with Preserved Ejection Fraction, HFpEF)是一种心力衰竭的亚型，复杂的病理机制导致无法为其制定一个标准的诊疗方案，因此人们不断研究寻找合适的辅助诊断技术以及有效的药物。现如今超声心动图、心脏磁共振和血清利钠肽等检查结合使得HFpEF的诊断准确率得到了极大的提高，各项临床试验证明了钠–葡萄糖共转运蛋白2抑制剂(Sodium-Glucose Co-Transporter 2 Inhibitor, SGLT2-i)等药物的使用明显改善了HFpEF患者的生存及预后。本文就HFpEF患者的诊断与治疗最新进展作一综述。Heart failure with preserved ejection fraction (HFpEF) is a subtype of heart failure whose complex pathologic mechanisms prevent a standard diagnosis and treatment regimen. Therefore, people continue to search for appropriate auxiliary diagnostic technology and effective drugs. Nowadays, the diagnostic accuracy of HFpEF has been greatly improved by the combination of echocardiography, cardiac magnetic resonance and serum natriuretic peptide. Various clinical trials have demonstrated that the use of drugs such as Sodium-glucose co-transporter 2 inhibitor (SGLT2-i) can significantly improve the survival and prognosis of HFpEF patients. This article reviews the recent progress in diagnosis and treatment of HFpEF patients.
No takes yet. Share an insight, caveat, or question.
冉 徐 (2025) conducted a review in Heart Failure with Preserved Ejection Fraction (HFpEF). Pharmacological therapies (SGLT2 inhibitors, GLP-1RAs, ARNI, MRA, Beta-blockers) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: